• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    10/28/24 6:08:43 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECX alert in real time by email
    SC 13D/A 1 tm2426988d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Tectonic Therapeutic, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    878972108

    (CUSIP Number)

     

    Atlas Venture

    Attention: Ommer Chohan, Chief Financial Officer

    300 Technology Square, 8th Floor

    Cambridge, MA 02139 USA

    (857) 201-2700

    (Name, Address and Telephone Number of Person Authorized to

    Receive Notices and Communications)

     

    October 24.2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP 878972108   Page 2 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    ATLAS VENTURE FUND X, L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    WC

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0

      8  

    SHARED VOTING POWER:

    9,1711

      9  

    SOLE DISPOSITIVE POWER:

    0

      10  

    SHARED DISPOSITIVE POWER:

    9,1711

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    9,1711

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    0.1%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN

     

    1 As described in Item 5 below, Atlas Venture Fund X, L.P., a Delaware limited partnership (“Atlas X”) directly holds 9,171 shares of the Issuer’s Common Stock. Atlas Venture Associates X, L.P., a Delaware limited partnership (“AVA X LP”) and Atlas Venture Associates X, LLC, a Delaware limited liability company (“AVA X LLC” and together with Atlas X and AVA X LP, the “Fund X Reporting Persons”) beneficially own the shares of the Issuer’s Common Stock held by Atlas X. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X.
       
    2 This percentage is calculated based upon 14,734,479 outstanding shares of Common Stock of the Issuer as of August 9, 2024, as reported in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024.

     

     

     

     

    CUSIP 878972108   Page 3 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    ATLAS VENTURE ASSOCIATES X, L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0

      8  

    SHARED VOTING POWER:

    10,8801

      9  

    SOLE DISPOSITIVE POWER:

    0

      10  

    SHARED DISPOSITIVE POWER:

    10,8801

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    10,8801

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    0.1%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN

     

    1 As described in Item 5 below, Atlas X and AVA X LP directly hold 9,171 and 1,709 shares of the Issuer’s Common Stock, respectively. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X and AVA X LLC has voting and dispositive power over the shares held by AVA X LP.
       
    2 This percentage is calculated based upon 14,734,479 outstanding shares of Common Stock of the Issuer as of August 9, 2024, as reported in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024.

     

     

     

     

    CUSIP 878972108   Page 4 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    Atlas Venture Associates X, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0

      8  

    SHARED VOTING POWER:

    10,8801

      9  

    SOLE DISPOSITIVE POWER:

    0

      10  

    SHARED DISPOSITIVE POWER:

    10,8801

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    10,8801

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    0.1%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    OO

     

    1 As described in Item 5 below, Atlas X and AVA X LP directly hold 9,171  and 1,709 shares of the Issuer’s Common Stock, respectively. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has voting and dispositive power over the shares held by Atlas X and AVA X LLC has voting and dispositive power over the shares held by AVA X LP.
       
    2 This percentage is calculated based upon 14,734,479 outstanding shares of Common Stock of the Issuer as of August 9, 2024, as reported in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024.

     

     

     

     

    CUSIP 878972108   Page 5 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    Atlas Venture Opportunity Fund I, L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    WC

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0

      8  

    SHARED VOTING POWER:

    67,5671

      9  

    SOLE DISPOSITIVE POWER:

    0

      10  

    SHARED DISPOSITIVE POWER:

    67,5671

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    67,5671

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    0.5%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN

     

    1 As described in Item 5 below, Atlas Venture Opportunity Fund I, L.P., a Delaware limited partnership (“AVOF”), Atlas Venture Associates Opportunity I, L.P., a Delaware limited partnership (“AVAO LP”) and Atlas Venture Associates Opportunity I, LLC, a Delaware limited liability company (“AVAO LLC” and together with AVOF and AVAO LP, the “Opportunity Fund Reporting Persons”) beneficially own 67,567 shares of the Issuer’s Common Stock. All of these shares are held by AVOF. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF.
       
    2 This percentage is calculated based upon 14,734,479 outstanding shares of Common Stock of the Issuer as of August 9, 2024, as reported in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024.

     

     

     

     

    CUSIP 878972108   Page 6 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    Atlas Venture Associates Opportunity I, L.P.

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0

      8  

    SHARED VOTING POWER:

    67,5671

      9  

    SOLE DISPOSITIVE POWER:

    0

      10  

    SHARED DISPOSITIVE POWER:

    67,5671

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    67,5671

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    0.5%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    PN

     

    1 As described in Item 5 below, AVOF, AVAO LP and AVAO LLC beneficially own 67,567 shares of the Issuer’s Common Stock. All of these shares are held by AVOF. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF.
       
    2 This percentage is calculated based upon 14,734,479 outstanding shares of Common Stock of the Issuer as of August 9, 2024, as reported in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024.

     

     

     

     

    CUSIP 878972108   Page 7 of 10

     

    1  

    NAMES OF REPORTING PERSONS:

    Atlas Venture Associates Opportunity I, LLC

    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a) ¨ (b) x

    3   SEC USE ONLY:
    4  

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

    AF

    5  

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ¨

    6  

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
      7  

    SOLE VOTING POWER:

    0

      8  

    SHARED VOTING POWER:

    67,5671

      9  

    SOLE DISPOSITIVE POWER:

    0

      10  

    SHARED DISPOSITIVE POWER:

    67,5671

    11  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

    67,5671

    12  

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

    ¨

    13  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

    0.5%2

    14  

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

    OO

     

    1 As described in Item 5 below, AVOF,  AVAO LP and AVAO LLC beneficially own 67,567 shares of the Issuer’s Common Stock. All of these shares are held by AVOF. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVAO LP and AVAO LLC has voting and dispositive power over the shares held by AVOF. As such, each of the Opportunity Fund Reporting Persons share voting and dispositive power with respect to the shares held by AVOF.
       
    2 This percentage is calculated based upon 14,734,479 outstanding shares of Common Stock of the Issuer as of August 9, 2024, as reported in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024.

     

     

     

     

    CUSIP 878972108   Page 8 of 10

     

    INTRODUCTION

     

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) is being filed as an amendment to the statement on Schedule 13D relating to common stock, par value $0.0001 per share (the “Common Stock”) of Tectonic Therapeutic, Inc. (formerly, AVROBIO, Inc.), a Delaware corporation (the “Issuer” or “Tectonic”), as filed with the Securities and Exchange Commission (the “SEC”) on July 30, 2019 (the “Initial Schedule 13D”). All capitalized terms not otherwise defined herein shall have the meanings ascribed to the terms in the Initial Schedule 13D. This Amendment No. 1 is being filed to report the sale of shares by Atlas X, as described herein, and gives effect to the 12-for-1 reverse stock of the Issuer’s common stock effected and completion of the reverse merger of the Issuer with Tectonic Therapeutic, Inc. (the “Reverse Merger”), each of which became effective on June 20, 2024.

     

    The Initial Schedule 13D is hereby amended and supplemented as follows and, except as expressly amended below, the Prior Schedule 13D remains in full force and effect.

     

    As of the date of this filing, the Reporting Persons’ are no longer the beneficial owner of more than five percent of Issuer’s securities and are no longer required to report the Reporting Persons’ holdings on a Schedule 13D.

     

    ITEM 1. SECURITY AND ISSUER

     

    The class of equity securities to which this Schedule 13D relates is common stock, par value $0.0001 per share (the “Common Stock”) of Tectonic Therapeutic, Inc. (formerly, AVROBIO, Inc.), a Delaware corporation (the “Issuer” or “Tectonic”). The principal executive offices of the Issuer are located at 490 Arsenal Way, Suite 210, Watertown, Massachusetts 02472.

     

    ITEM 2. IDENTITY AND BACKGROUND

     

    Item 2(b) of the Initial Schedule 13D is hereby amended and restated as follows:

     

    (b) The address of the principal place of business of each of the Reporting Persons is c/o 300 Technology Square, 8th Floor, Cambridge, Massachusetts 02139.

     

    ITEM 4. PURPOSE OF TRANSACTION

     

    Item 4 of the Initial Schedule 13D is hereby amended and supplemented as follows:

     

    Effective upon the completion of the Reverse Merger, Bruce Booth, D.Phil., resigned as a director of the Issuer.

     

     

     

     

    CUSIP 878972108   Page 9 of 10

     

    ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

     

    Item 5 of the Initial Schedule 13D is hereby amended and restated as follows:

     

    (a) (b) As of the date hereof, Atlas X is the record owner of 9,171 shares of Common Stock. AVA X LP is the general partner of Atlas X and AVA X LLC is the general partner of AVA X LP. Each of Atlas X, AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by Atlas X. As such, each of Atlas X, AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by Atlas X.

     

    As of the date hereof, AVA X LP is the record owner of 1,709 shares of Common Stock. AVA X LLC is the general partner of AVA X LP. Each of AVA X LP and AVA X LLC has shared voting and dispositive power over the shares held by AVA X LP. As such, each of AVA X LP and AVA X LLC may be deemed to beneficially own the shares held by AVA X LP.

     

    As of the date hereof, AVOF is the record owner of 67,567 shares of Common Stock. AVAO LP is the general partner of AVOF and AVAO LLC is the general partner of AVAO LP. Each of AVOF, AVAO LP and AVAO LLC has shared voting and dispositive power over the shares held by AVOF. As such, each of AVOF, AVAO LP and AVAO LLC may be deemed to beneficially own the shares held by AVOF.

     

    Each of the Fund X Reporting Persons and Opportunity Fund Reporting Persons may be deemed to beneficially own 0.1% and 0.5%, respectively, of the Issuer’s outstanding Common Stock, which percentages are calculated based upon 14,734,479 outstanding shares of Common Stock, as reported in the Issuer's prospectus supplement filed with the Securities and Exchange Commission on August 14, 2024.

     

    Collectively, the Reporting Persons beneficially own an aggregate of 78,447 shares of Common Stock, which represents 0.5% of the Issuer's outstanding Common Stock. The Fund X Reporting Persons and the Opportunity Fund Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes.

     

    (c) On October 24, 2024, Atlas X sold 300,000 shares of the Issuer’s Common Stock in a privately negotiated transaction with a single buyer for $33.59 per share.

     

    (d)

    No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Persons.

     

     

    (e) The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on June 20, 2024 by virtue of the closing of the Reverse Merger,

     

     

     

     

    CUSIP 878972108   Page 10 of 10

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: October 28, 2024

     

    ATLAS VENTURE FUND X, L.P.  
         
    By: Atlas Venture Associates X, L.P., its general partner  
    By: Atlas Venture Associates X, LLC, its general partner  
         
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
         
    ATLAS VENTURE ASSOCIATES X, L.P.  
         
    By: Atlas Venture Associates X, LLC, its general partner  
         
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
         
    ATLAS VENTURE ASSOCIATES X, LLC  
         
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
       
    ATLAS VENTURE OPPORTUNITY FUND I, L.P.  
       
    By: Atlas Venture Associates Opportunity I, L.P., its general partner  
    By: Atlas Venture Associates Opportunity I, LLC, its general partner  
       
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
       
    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.  
       
    By: Atlas Venture Associates Opportunity I, LLC, its general partner  
       
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  
       
    ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLC  
       
    By: /s/ Ommer Chohan  
    Name: Ommer Chohan  
    Title: Chief Financial Officer  

     

     

     

    Get the next $TECX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TECX

    DatePrice TargetRatingAnalyst
    7/21/2025$64.00Buy
    Truist
    6/11/2025$76.00Outperform
    Raymond James
    4/21/2025$51.00Outperform
    Mizuho
    11/20/2024$65.00Outperform
    Raymond James
    8/22/2024$55.00Overweight
    Wells Fargo
    6/26/2024Overweight
    Piper Sandler
    6/24/2024Buy
    TD Cowen
    More analyst ratings

    $TECX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springer Timothy A bought $2,299,015 worth of shares (141,923 units at $16.20), increasing direct ownership by 0.49% to 4,334,846 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/11/25 6:12:08 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $8,550,000 worth of shares (500,000 units at $17.10), increasing direct ownership by 2% to 4,313,558 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    4/9/25 5:38:10 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Springer Timothy A bought $39,999,977 worth of shares (789,294 units at $50.68), increasing direct ownership by 3% to 4,226,058 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    2/7/25 4:21:19 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tectonic Therapeutic to Participate in September Investor Conferences

    WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston, MAFormat:Investor Meetings   Cantor Global Healthcare Conference Date:September 4, 2025Time:2:10 PM EDTLocation:New York, NYFormat:Fireside ChatPresenters:Daniel Lochner, Chief F

    8/28/25 9:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights

    TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH) to expand the therapeutic breadth of TX45 Complete results from Part A of the TX45 Phase 1b clinical trial presented at ESC Heart Failure 2025 confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in subjects with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")Part B of the TX45 Phase 1b clinical trial in subjects with Group 2 Pulmonary Hypertension in Heart Failure with r

    8/7/25 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Joins Russell 3000® Index

    WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization.

    6/30/25 8:00:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Tectonic Therapeutic with a new price target

    Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00

    7/21/25 8:39:42 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on Tectonic Therapeutic with a new price target

    Raymond James resumed coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $76.00

    6/11/25 7:55:49 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Tectonic Therapeutic with a new price target

    Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

    4/21/25 8:39:06 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Reicin Alise covered exercise/tax liability with 859 shares, decreasing direct ownership by 0.40% to 213,485 units (SEC Form 4)

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    6/24/25 4:55:39 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Vitorovic Stefan

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    6/11/25 4:30:29 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Donenberg Phillip B.

    4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

    6/11/25 4:30:30 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    SEC Filings

    View All

    SEC Form 8-K filed by Tectonic Therapeutic Inc.

    8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    8/7/25 5:08:54 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Tectonic Therapeutic Inc.

    10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    8/7/25 4:04:36 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Tectonic Therapeutic Inc.

    EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)

    7/16/25 12:15:13 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Financials

    Live finance-specific insights

    View All

    Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF

    TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

    1/30/25 6:30:00 AM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights

    Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

    11/7/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights

    TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

    8/14/24 4:01:00 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tectonic Therapeutic Inc.

    SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    11/14/24 4:05:11 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/28/24 6:08:43 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tectonic Therapeutic Inc.

    SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

    10/24/24 5:12:09 PM ET
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care